Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut syndrome, Dravet syndrome, and acute repetitive seizures. Several novel therapies have reached or will soon reach the U.S. market that will help address the needs of patients within these niche segments; however, this wave of premium-priced brands—some with orphan-level pricing—will enter a cost-sensitive market dominated by generics. Anticipating payers’ receptivity to emerging products and how future coverage policies could affect patient access and neurologists’ treatment choice are crucial for drug developers entering an increasingly crowded market for a clinically complex disease.

QUESTIONS ANSWERED

  • What is the current state of coverage for key AED brands in the U.S. market? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
  • How receptive are payers to late-phase emerging therapies? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?
  • What actions can developers take to optimize market access?

Markets covered: United States

Key companies: Aquestive Therapeutics, GW Pharmaceuticals, Neurelis, SK Biopharmaceuticals, UCB, Zogenix, Biocodex, Sunovion, Eisai

Key drugs covered: Generic SOCs, Vimpat, Fycompa, Aptiom, Briviact, Epidiolex, Xcopri, Nayzilam, Valtoco, Fintepla, padsevonil, Libervant, Diacomit

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Table of contents

  • Epilepsy - Access & Reimbursement - Detailed, Expanded Analysis (US)

Author(s): Niyati Khetarpal, Ph.D

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”


Related Reports

Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogen...

View Details

Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to

View Details

Epilepsy - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US) Total

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selectin...

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2019

Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition r...

View Details